The FDA has set a Feb. 21 target decision on the Bysanti NDA. ・Vanda submitted the NDA in March 2025 for Bysanti to treat acute bipolar I disorder and schizophrenia. ・In May, the FDA said the ...

Vanda Pharmaceuticals had 9% revenue growth and heavy losses with a 1.4x sales valuation and a PDUFA date. Check out why VNDA stock is downgraded to hold.

Vanda Pharmaceuticals, a company that develops medicines for conditions with limited to no treatment options, has signed a multi-year partnership with the New York Islanders to become their jersey ...

B. Riley has initiated coverage of Vanda Pharmaceuticals (VNDA) at buy saying that the company is currently trading at a valuation that is a "historic discount" and is "untenable." The firm has a ...

Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder Provided by PR Newswire Jan 8, 2026, 4:00:00 AM Vanda Pharmaceuticals ...

The end of the trading week likely can't come fast enough for Vanda Pharmaceuticals (NASDAQ: VNDA). The commercial-stage biotech's stock took an almost 6% hit on Thursday, following some dispiriting ...

Vanda asked Martin Makary, the Commissioner of the Food and Drug Administration, to review the decision made by Jacqueline Corrigan-Curay, the departing director of the FDA's Center for Drug ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2025 Earnings Call Transcript February 11, 2026 Vanda Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-2.39 EPS, expectations were ...

Multiyear agreement includes exclusive Monumental Sports Network studio entitlement, activations across Capitals, Wizards, and Mystics, and deep integration via community and media platforms For ...

Despite a 9% revenue increase, Vanda Pharmaceuticals Inc (VNDA) faces significant net losses and rising operating expenses.

WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program. Gastroparesis is a serious digestive ...

The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) ...